PEMETREXED DIPOTASSIUM
| Brand name | AXTLE |
|---|---|
| Active ingredient | PEMETREXED DIPOTASSIUM |
| Strength | EQ 500MG BASE/VIAL |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | June 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12721811 | June 2045 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.